Generic Name and Formulations:
Candesartan cilexetil 4mg, 8mg, 16mg, 32mg; tabs.
Company:
AstraZeneca Pharmaceuticals
Heart failure (NYHA class II-IV and ejection fraction ≤40%), to reduce risk of death and hospitalization; alone or with an ACE inhibitor.
≥18yrs: Initially 4mg once daily; double daily dose at 2-week intervals as tolerated to target 32mg once daily. Salt/volume depleted or moderate hepatic impairment: consider lower initial dose.
<18yrs: not recommended.
Angiotensin II receptor blocker.
Fetal toxicty may develop; discontinue if pregnancy is detected. Correct hypovolemia before starting or monitor closely. Monitor BP, serum creatinine, and K+ during dose increases, then periodically. Hepatic or renal impairment. Severe CHF. Renal artery stenosis. Surgery. Elderly. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.
Monitor lithium and for hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume-depleted).
Back pain, dizziness, upper respiratory tract infection, pharyngitis, rhinitis, rhabdomyolysis (rare).
Tabs 4mg, 8mg—30; 16mg, 32mg—30, 90
Hypertension.
Individualize. ≥18yrs: Monotherapy and not volume-depleted: initially 16mg once daily; usual range: 8–32mg per day once daily or in 2 divided doses. Salt/volume depleted or moderate hepatic impairment: consider lower initial dose. May add diuretic if needed.
<1yr or CrCl<30mL/min: not recommended. Give once daily or in 2 divided doses. 1–<6yrs (may give oral susp if unable to swallow tabs): initially 0.2mg/kg/day; usual range: 0.05–0.4mg/kg/day. 6–<17yrs (<50kg): initially 4–8mg/day; usual range: 2–16mg/day; (>50kg): initially 8–16mg/day; usual range: 4–32mg/day. Salt/volume depletion: consider lower initial dose.
Angiotensin II receptor blocker.
Fetal toxicty may develop; discontinue if pregnancy is detected. Correct hypovolemia before starting or monitor closely. Hepatic or renal impairment. Severe CHF. Renal artery stenosis. Surgery. Elderly. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.
Monitor lithium and for hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume-depleted).
Back pain, dizziness, upper respiratory tract infection, pharyngitis, rhinitis, rhabdomyolysis (rare).
Tabs 4mg, 8mg—30; 16mg, 32mg—30, 90